よむ、つかう、まなぶ。

MC plus(エムシープラス)は、診療報酬・介護報酬改定関連のニュース、

資料、研修などをパッケージした総合メディアです。


09参考資料1-3 9価ヒトパピローマウイルス( HPV )ワクチン ファクトシート (41 ページ)

公開元URL https://www.mhlw.go.jp/stf/shingi2/0000192554_00024.html
出典情報 厚生科学審議会予防接種・ワクチン分科会 予防接種基本方針部会(第49回 10/4)《厚生労働省》
低解像度画像をダウンロード

資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。

1553

3. 引⽤⽂献

1588

15. 厚⽣労働省.がん予防重点健康教育及びがん検診実施のための指針.(健発第03310

1589

58号平成20年3⽉31⽇厚⽣労働省健康局⻑通知別添)
(平成28年2⽉4⽇⼀部改正)

1590

https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000111662.pdf

1555

1. Bzhalava D, Eklund C, Dillner J. (2015). International standardization and classification

1591

16.

1556

of human papillomavirus types. Virology 476:341‒344.

1592

association. Rev Med Virol 25 Suppl 1(Suppl Suppl 1): 2-23.

1557

https://doi.org/10.1016/j.virol.2014.12.028

1593

17. Giuliano, A. R., et al. (2011). Incidence and clearance of genital human papillomavirus

1558

2.

1594

infection in men (HIM): a cohort study. Lancet 377(9769): 932-940.

1554

Muñoz, N., et al. (2003). Epidemiologic classification of human papillomavirus types

Doorbar, J., et al. (2015). Human papillomavirus molecular biology and disease

1559

associated with cervical cancer. N Engl J Med 348(6): 518-527.

1595

18. Backes, D. M., et al. (2009). Systematic review of human papillomavirus prevalence in

1560

3. Muñoz, N., et al. (2004). Against which human papillomavirus types shall we vaccinate

1596

invasive penile cancer. Cancer Causes Control 20(4): 449-457.

1561

and screen? The international perspective. Int J Cancer 111(2): 278-285.

1597

19. Arbyn, M., et al. (2020). Estimates of incidence and mortality of cervical cancer in 2018:

1562

4.

1598

a worldwide analysis. Lancet Glob Health 8(2): e191-e203.

1563

Vaccine 24 Suppl 3: S3/11-25.

1599

https://www.ncbi.nlm.nih.gov/pubmed/31812369

1564

5.

1600

20. Baldur-Felskov, B., et al. (2014). Incidence of cervical lesions in Danish women before

1565

application. Nat Rev Cancer 2(5): 342-350.

1601

and after implementation of a national HPV vaccination program. Cancer Causes Control

1566

6. Bosch, F. X., et al. (2012). Reframing cervical cancer prevention. Expanding the field

1602

25(7): 915-922. https://www.ncbi.nlm.nih.gov/pubmed/24797870

1567

towards prevention of human papillomavirus infections and related diseases. Vaccine 30

1603

21. Gertig, D. M., et al. (2013). Impact of a population-based HPV vaccination program on

1568

Suppl 5: F1-11.

1604

cervical abnormalities: a data linkage study. BMC Med 11: 227.

1569

7. Moscicki, A. B., et al. (2012). Updating the natural history of human papillomavirus and

1605

https://www.ncbi.nlm.nih.gov/pubmed/24148310

1570

anogenital cancers. Vaccine 30 Suppl 5(0 5): F24-33.

1606

22. Kjaer, S. K., et al. (2018). A 12-Year Follow-up on the Long-Term Effectiveness of the

1571

8. Demarco, M., et al. (2020). A study of type-specific HPV natural history and implications

1607

Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. Clin Infect Dis 66(3):

1572

for contemporary cervical cancer screening programs. EClinicalMedicine 22: 100293.

1608

339-345.

1573

9. Castle, P. E., et al. (2006). Human papillomavirus prevalence in women who have and

1609

23. Pollock, K. G., et al. (2014). Reduction of low- and high-grade cervical abnormalities

1574

have not undergone hysterectomies. J Infect Dis 194(12): 1702-1705.

1610

associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 111(9):

1575

10. Moscicki, A. B., et al. (2004). Regression of low-grade squamous intra-epithelial lesions

1611

1824-1830 https://www.ncbi.nlm.nih.gov/pubmed/25180766

1576

in young women. Lancet 364(9446): 1678-1683.

1612

24.

1577

11. Jacobs, M. V., et al. (2000). Distribution of 37 mucosotropic HPV types in women with

1613

cancers. Int J Cancer 142(10): 2186-2187.

1578

cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types.

1614

https://www.ncbi.nlm.nih.gov/pubmed/29280138

1579

Int J Cancer 87(2): 221-227.

1615

25. Guo, F., et al. (2018). Cervical Cancer Incidence in Young U.S. Females After Human

1580

12. Hildesheim, A., et al. (2007). Effect of human papillomavirus 16/18 L1 viruslike particle

1616

Papillomavirus Vaccine Introduction. Am J Prev Med 55(2): 197-204.

1581

vaccine among young women with preexisting infection: a randomized trial. Jama 298(7):

1617

https://www.ncbi.nlm.nih.gov/pubmed/29859731

1582

743-753.

1618

26. Lei, J., et al. (2020). HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl

1583

13. Woodman, C. B., et al. (2007). The natural history of cervical HPV infection: unresolved

1619

J Med 383(14): 1340-1348. https://www.ncbi.nlm.nih.gov/pubmed/32997908

1584

issues. Nat Rev Cancer 7(1): 11-22.

1620

27. 国⽴がん研究センター がん情報サービス. がんに関する統計データのダウンロード.

Parkin, D. M. and F. Bray (2006). Chapter 2: The burden of HPV-related cancers.
zur Hausen, H. (2002). Papillomaviruses and cancer: from basic studies to clinical

Luostarinen, T., et al. (2018). Vaccination protects against invasive HPV-associated

1585

14. Matsumoto, K., et al. (2011). Predicting the progression of cervical precursor lesions by

1621

https://ganjoho.jp/reg_stat/statistics/dl/index.html

1586

human papillomavirus genotyping: a prospective cohort study. Int J Cancer 128(12): 2898-

1622

28. Katanoda, K., et al. (2017). Childhood, adolescent and young adult cancer incidence in

1587

2910.

1623

Japan in 2009-2011. Jpn J Clin Oncol 47(8): 762-771.

81

82